These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28805970)

  • 21. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
    Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
    J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes.
    Chen Y; Song M; Riley JP; Hu CC; Peng X; Scheuner D; Bokvist K; Maiti P; Kahl SD; Montrose-Rafizadeh C; Hamdouchi C; Miller AR
    Pharmacol Res Perspect; 2016 Dec; 4(6):e00278. PubMed ID: 28097011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined Deletion of Free Fatty-Acid Receptors 1 and 4 Minimally Impacts Glucose Homeostasis in Mice.
    Croze ML; Guillaume A; Ethier M; Fergusson G; Tremblay C; Campbell SA; Maachi H; Ghislain J; Poitout V
    Endocrinology; 2021 Mar; 162(3):. PubMed ID: 33543237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HWL-088, a new potent free fatty acid receptor 1 (FFAR1) agonist, improves glucolipid metabolism and acts additively with metformin in ob/ob diabetic mice.
    Chen Y; Ren Q; Zhou Z; Deng L; Hu L; Zhang L; Li Z
    Br J Pharmacol; 2020 May; 177(10):2286-2302. PubMed ID: 31971610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production.
    Miller C; Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Bunzel M; Cao J; Souza S; Thomas-Fowlkes B; Di Salvo J; Weinglass AB; Li X; Myers RW; Knagge K; Carrington PE; Hagmann WK; Trujillo ME
    PLoS One; 2017; 12(5):e0176182. PubMed ID: 28542610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.
    Matsumoto K; Yoshitomi T; Ishimoto Y; Tanaka N; Takahashi K; Watanabe A; Chiba K
    J Pharmacol Exp Ther; 2018 Dec; 367(3):509-517. PubMed ID: 30217957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression of free fatty acid receptor 1 expression in pancreatic β-cells in obese type 2 diabetic db/db mice: a potential role of pancreatic and duodenal homeobox factor 1.
    Kohara K; Obata A; Kimura T; Shimoda M; Moriuchi S; Okauchi S; Hirukawa H; Mune T; Kaku K; Kaneto H
    Endocr J; 2019 Jan; 66(1):43-50. PubMed ID: 30333365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships.
    Paul A; Nahar S; Nahata P; Sarkar A; Maji A; Samanta A; Karmakar S; Maity TK
    Eur J Med Chem; 2024 Jan; 264():115990. PubMed ID: 38039791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease.
    Lan H; Hoos LM; Liu L; Tetzloff G; Hu W; Abbondanzo SJ; Vassileva G; Gustafson EL; Hedrick JA; Davis HR
    Diabetes; 2008 Nov; 57(11):2999-3006. PubMed ID: 18678612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents.
    Lin DC; Zhang J; Zhuang R; Li F; Nguyen K; Chen M; Tran T; Lopez E; Lu JY; Li XN; Tang L; Tonn GR; Swaminath G; Reagan JD; Chen JL; Tian H; Lin YJ; Houze JB; Luo J
    PLoS One; 2011; 6(11):e27270. PubMed ID: 22087278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stimulation of insulin secretion by acetylenic fatty acids in insulinoma MIN6 cells through FFAR1.
    Nishino K; Uesugi H; Hirasawa A; Ohtera A; Miyamae Y; Neffati M; Isoda H; Kambe T; Masuda S; Irie K; Nagao M
    Biochem Biophys Res Commun; 2020 Jan; 522(1):68-73. PubMed ID: 31740001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic Exposure to SCO-267, an Allosteric GPR40 Full Agonist, Is Effective in Improving Glycemic Control in Rats.
    Koyama R; Ookawara M; Watanabe M; Moritoh Y
    Mol Pharmacol; 2021 Apr; 99(4):286-293. PubMed ID: 33547250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists.
    Jiang XW; Jiang BE; Liu H; Liu ZT; Hu LL; Liu M; Lu W; Zhang HK
    Eur J Med Chem; 2018 Oct; 158():123-133. PubMed ID: 30212763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N
    Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Hirouchi M; Yoneyama T; Ito S; Toda N
    ACS Med Chem Lett; 2015 Mar; 6(3):266-70. PubMed ID: 25815144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist.
    Negoro N; Sasaki S; Mikami S; Ito M; Suzuki M; Tsujihata Y; Ito R; Harada A; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Tanaka T; Kogame A; Matsunaga S; Yasuma T; Momose Y
    ACS Med Chem Lett; 2010 Sep; 1(6):290-4. PubMed ID: 24900210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peroxisome proliferator-activated receptor gamma (PPARG) modulates free fatty acid receptor 1 (FFAR1) dependent insulin secretion in humans.
    Wagner R; Hieronimus A; Lamprinou A; Heni M; Hatziagelaki E; Ullrich S; Stefan N; Staiger H; Häring HU; Fritsche A
    Mol Metab; 2014 Sep; 3(6):676-80. PubMed ID: 25161890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion.
    Tanaka H; Yoshida S; Oshima H; Minoura H; Negoro K; Yamazaki T; Sakuda S; Iwasaki F; Matsui T; Shibasaki M
    J Pharmacol Exp Ther; 2013 Sep; 346(3):443-52. PubMed ID: 23853170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FFAR1 is involved in both the acute and chronic effects of palmitate on insulin secretion.
    Kristinsson H; Smith DM; Bergsten P; Sargsyan E
    Endocrinology; 2013 Nov; 154(11):4078-88. PubMed ID: 24035997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Xelaglifam, a novel GPR40/FFAR1 agonist, exhibits enhanced β-arrestin recruitment and sustained glycemic control for type 2 diabetes.
    Yoon J; Lee DG; Song H; Hong D; Park JS; Hong C; An KM; Lee JW; Park JT; Yoon H; Tak J; Kim SG
    Biomed Pharmacother; 2024 Aug; 177():117044. PubMed ID: 38941892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.